Login / Signup

Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.

Yu ZhangFei WangHao-Ran SunYa-Kai HuangJian-Peng GaoHua Huang
Published in: Journal of cancer research and clinical oncology (2021)
Combining apatinib with PD-L1 blockade treatment synergistically enhances antitumor immune responses and promotes HEV formation in GC.
Keyphrases
  • immune response
  • dendritic cells
  • toll like receptor
  • inflammatory response